EP300 and acute lymphoblastic leukemia: The objective of this study is to report the first documented pediatric DS-ALL case harboring five concurrent high-risk genomic lesions (NRAS p.G13D, JAK2 p.R683G, EP300 p.Q1766*, P2RY8–CRLF2 fusion, and iAMP21).